GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » Owner Earnings per Share (TTM)

BRNS (Barinthus Biotherapeutics) Owner Earnings per Share (TTM) : -1.38 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Barinthus Biotherapeutics's Owner Earnings per Share (TTM) ended in Dec. 2024 was $-1.38. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Barinthus Biotherapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:



BRNS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 30.88
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Barinthus Biotherapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.51. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.55. It's PE Ratio (TTM) ratio for today is At Loss.

Barinthus Biotherapeutics's EPS without NRI for the three months ended in Dec. 2024 was $-0.51. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.55. It's PE Ratio without NRI ratio for today is At Loss.


Barinthus Biotherapeutics Owner Earnings per Share (TTM) Historical Data

The historical data trend for Barinthus Biotherapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics Owner Earnings per Share (TTM) Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - - -1.38

Barinthus Biotherapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -2.00 -1.38

Competitive Comparison of Barinthus Biotherapeutics's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Barinthus Biotherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Barinthus Biotherapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's Price-to-Owner-Earnings falls into.


;
;

Barinthus Biotherapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Barinthus Biotherapeutics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -61.07
Depreciation, Depletion and Amortization 5.80
Change In Deferred Tax -0.04
5Y Average of Maintenance Capital Expenditure 2.56
Change In Working Capital 2.60
Shares Outstanding (Diluted Average) 40.16

1. Start with "Net Income" from income statement. Barinthus Biotherapeutics's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-61.07 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Barinthus Biotherapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2024 was $5.80 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Barinthus Biotherapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.04 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $2.56 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Barinthus Biotherapeutics's 5-Year Average Maintenance Capital Expenditure = $2.56 Mil

5. "Change In Working Capital" is from cashflow statement. Barinthus Biotherapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 was $2.60 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Barinthus Biotherapeutics's Shares Outstanding (Diluted Average) for the months ended in Dec. 2024 was 40.155 Mil.

Barinthus Biotherapeutics's Onwer Earnings Per Share for Dec. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -61.074 +5.8+-0.044
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-2.5598688853896+2.601)/40.155
=-1.38

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.7034/-1.38
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Barinthus Biotherapeutics Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Barinthus Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, GBR, OX11 0DF
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Executives
Joseph Scheeren director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright director, officer: Chief Executive Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier officer: Chief Scientific Officer C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown officer: Chief Financial Officer VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths officer: Chief Business Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis officer: Chief Operating Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall officer: Chief Medical Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans officer: Chief Scientific Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov officer: Chief Financial Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE

Barinthus Biotherapeutics Headlines

From GuruFocus

Vaccitech to Present at Upcoming November Investors Conferences

By Value_Insider Value_Insider 11-09-2022